Company Encyclopedia
View More
name
PAVmed
PAVM.US
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.
1.407 T
PAVM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking140/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-338.64%E
    • Profit Margin10672.41%A
    • Gross Margin-1000.00%E
  • Growth ScoreD
    • Revenue YoY-99.28%E
    • Net Profit YoY-104.05%E
    • Total Assets YoY24.61%A
    • Net Assets YoY374.71%A
  • Cash ScoreE
    • Cash Flow Margin-4.87%D
    • OCF YoY-99.28%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio32.26%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    PAVmed’s Earnings Call: Triumphs and Trials

    PAVmed's Q3 earnings call highlighted both achievements and challenges. Key milestones include Medicare endorsement for EsoGuard and strategic partnerships for Veris. Lucid Diagnostics raised nearly $27 million, ensuring financial stability. Challenges include debt restructuring and stagnant EsoGuard revenue. PAVmed aims to expand core assets, secure Medicare coverage, and advance its implantable device towards FDA approval by 2026. The company is also pursuing a 510(k) pathway for endoscopic imaging technology. Investors are watching how PAVmed navigates these challenges and capitalizes on strategic initiatives.

    Tip Ranks·
    US
    PAVM
    +7.03%
    Tip Ranks·
    US
    PAVM
    +7.03%

    PAVmed Announces Q3 2025 Financial Results and Updates

    PAVmed Inc. announced its Q3 2025 financial results, reporting a GAAP net loss of $6.3 million and cash reserves of $3.1 million. Key developments include Veris Health's commercial launch, a new licensing agreement with Duke University, and Lucid Diagnostics' $1.2 million revenue from EsoGuard tests. The company faces financial challenges, with a Hold rating and $0.50 price target on its stock. PAVmed operates in medical technology, focusing on innovative solutions through subsidiaries like Lucid Diagnostics and Veris Health.

    Tip Ranks·
    US
    PAVM
    +7.03%
    Tip Ranks·
    US
    PAVM
    +7.03%

    PAVmed | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 5 K

    LB filings·
    US
    PAVM
    +7.03%
    LB filings·
    US
    PAVM
    +7.03%

    PAVmed reports third quarter 2025 financial results

    PAVmed Inc. reported a non-GAAP adjusted loss of $0.4 million for Q3 2025, with cash equivalents at $3.1 million. Veris Health launched a strategic partnership and resumed development of its monitor. PAVmed signed a letter of intent for new imaging technology. This AI-generated brief is informational and not financial advice.

    Reuters·
    US
    PAVM
    +7.03%
    Reuters·
    US
    PAVM
    +7.03%

    PAVmed | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 5 K

    LB filings·
    US
    PAVM
    +7.03%
    LB filings·
    US
    PAVM
    +7.03%
    © 2025 Longbridge｜Disclaimer